Renal tubular diseases are rare conditions caused by genetic mutations or metabolic abnormalities, disrupting kidney function. With our expert team and advanced platforms, we aim to provide comprehensive therapeutic development services for renal tubular diseases, driving the discovery of effective treatments for these challenging disorders.
Introduction to Renal Tubular Diseases
Renal tubular diseases are rare disorders that impair the function of the kidney's tubular structures, often due to genetic mutations or metabolic imbalances. These conditions disrupt the kidneys' ability to properly process and transport essential substances, leading to significant health challenges. The prevalence varies widely depending on the specific disorder, but many of these conditions occur in less than 1 in 100,000 individuals, classifying them as rare diseases.
Pathogenesis of Renal Tubular Diseases
Renal tubular diseases arise from various etiologies, including genetic mutations, environmental factors, and systemic conditions. Genetic mutations can disrupt tubular transport processes, leading to electrolyte imbalances and metabolic disturbances. Environmental toxins and medications may cause tubular injury through direct toxicity or by inducing oxidative stress. Systemic diseases such as diabetes and hypertension can impair tubular function by causing ischemia or promoting inflammatory pathways.
Fig.1 ALDH2 exerts protective roles in various organs and cells by inhibiting ROS and 4-HNE. (Li, J., et al., 2024)
Therapeutics Development for Renal Tubular Diseases
Renal tubular diseases present unique challenges due to their intricate pathophysiology, often involving genetic mutations and complex biochemical pathways. As we deepen our understanding of these disorders, cutting-edge therapeutic strategies such as gene therapy and therapeutic antibody development offer promising avenues for treatment.
Therapeutic Antibody
Therapeutic antibodies aim to modulate immune responses or block harmful pathways in renal tubular diseases. Monoclonal antibodies targeting specific proteins, such as those involved in urate transport, have been developed to alleviate conditions like familial renal hypouricemia. These antibodies provide targeted therapy that can prevent disease progression and preserve renal function.
Gene Therapy
Gene therapy for renal tubular diseases focuses on correcting genetic defects at their source. Recent advancements have demonstrated success in using CRISPR-Cas9 technology to edit genes responsible for tubular dysfunctions. An example includes targeting mutations in the SLC12A gene, which has shown promising results in preclinical models.
Our Services
At our company, we specialize in providing end-to-end support for the development of innovative therapies targeting renal tubular diseases. By leveraging our team of experienced nephrologists, geneticists, and pharmaceutical scientists, we employ state-of-the-art technologies to drive the progress of your therapeutic endeavours.
Diseases Model Development
- Genetically Engineering Model
- Induced Disease Model
- Humanized Animal Model
- Syngeneic Model
- Xenograft Model
Types of Renal Tubular Diseases
Renal tubular diseases encompass a varied assortment of kidney disorders, each defined by specific genetic mutations and distinct pathophysiological features. Gaining a comprehensive understanding of the different types of renal tubular diseases is essential for crafting precise and effective therapeutic approaches.
| A-F |
F-M |
N-W |
- Andersen-Tawil Syndrome (ATS)
- Bartter's Syndrome
- Dent's Disease
- Dicarboylic Aminoaciduria
- Familial Hypocalciuric Hypercalcaemia (FHH)
- Familial Juvenile Hyperuricaemic Nephropathy (FJHN)
- Fanconi-Bickel syndrome
|
- Gitelman's Syndrome
- Gordon's Syndrome
- Hereditary Renal Hypouricaemia
- Hypophosphataemic Rickets
- Liddle's Syndrome
- Lowe Oculocerebrorenal Syndrome
- Lysinuric Protein Intolerance
|
- Nephrogenic Diabetes Insipidus type 1
- Nephrogenic Syndrome of Inappropriate Antidiuresis
- Pseudohypoaldosteronism type 1
- Renal Glucosuria
- Renal Tubular Acidosis
- SeSAME Syndrome
|
At our company, we are committed to providing comprehensive, one-stop preclinical development services that cover every aspect. We also offer pharmacokinetics and drug safety evaluation services to ensure a complete and seamless experience for our clients If you are interested in our services, please don't hesitate to contact us.
References
- Guo, W., P. Ji, and Y. Xie. "Genetic Diagnosis and Treatment of Hereditary Renal Tubular Disease with Hypokalemia and Alkalosis." J Nephrol 36.2 (2023): 575-91.
- Li, J., et al. "From Rare Disorders of Kidney Tubules to Acute Renal Injury: Progress and Prospective." Kidney Dis (Basel) 10.2 (2024): 153-66.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
